Charles River ($CRL): Q4 DSA net book-to-bill ~1.1x as demand improved through H2 2025, led by small/mid…
Filed with the SEC on · Summarized by InvestorsBot
Charles River ($CRL): Q4 DSA net book-to-bill ~1.1x as demand improved through H2 2025, led by small/mid biotech. Company expects organic revenue growth at the top end of 2026 guidance "at least flat" (consolidated & DSA) with return to growth in H2 2026. 📈🧪 #CRL #biotech
$CRL to acquire K.F. (Cambodia) Ltd for ~ $510M (subject to adjustments); expected close early Q1 2026. Not expected to generate meaningful 3rd‑party revenue but accretive to non‑GAAP EPS ~+$0.25 in 2026 and ~$0.60 in 2027. 🐒💰 #M&A #NHP
$CRL exercised option to buy remaining 79% of PathoQuest SAS for €51.6M (~$60M); expected close by end Q1 2026. PathoQuest est. to generate $15–20M revenue in 2026; deal not expected to materially impact 2026/27 results. Company targeting >$100M cost savings in 2026. 🔬💸 #M&A #biomanufacturing